Significance
============

1.  A moderate level of evidence was obtained for pain catastrophizing as an independent predictor of chronic post-surgical pain following total knee arthroplasty (TKA);

2.  Lack of uniformity in data capture, particularly in pain outcome measures, precludes meta-analysis and underscores the need for consensus regarding standardized reporting of chronic pain outcomes;

3.  Future directions for research include larger study samples, improved covariate adjustment (especially for analgesic use, depression, and anxiety), adoption of consensus guidelines on outcome measures for clinically relevant chronic pain, optimal thresholds for pain catastrophizing levels that predict adverse pain outcomes, and assessment of interventions aimed to reduce the negative effects of pain catastrophizing symptoms on chronic pain outcomes.

Introduction
============

With the aging population and mounting obesity epidemic, rates of TKA have increased dramatically in the last two decades such that TKA now constitutes one of the most common and costly medical procedures in the US and Canada.[@b1-jpr-8-021]--[@b3-jpr-8-021] Although studies employing survivorship and surgeon-based measures have generally reported TKA success rates exceeding 80%,[@b4-jpr-8-021] these measures do not account for post-surgical pain following TKA such that chronic pain remains a major health burden for many patients.[@b5-jpr-8-021] Specifically, studies utilizing patient-based outcome measures have indicated that 6%--30% of patients continue to experience chronic pain in the months and years after TKA.[@b6-jpr-8-021]--[@b10-jpr-8-021] This critical gap in recovery outcomes has prompted investigators to search for modifiable risk factors for chronic pain outcomes after TKA surgery.

Converging evidence from the literature on non-surgical chronic pain suggests that pain disability does not result solely from the severity of the pain, but rather, is largely influenced by patients' interpretation and adjustment to their pain.[@b11-jpr-8-021]--[@b13-jpr-8-021] In particular, pain catastrophizing has emerged as an important factor in chronic pain onset, severity, and duration, and may represent an independent predictor of poor treatment outcomes including the development of chronic pain after surgery.[@b14-jpr-8-021] Pain catastrophizing is a multidimensional construct comprising elements of rumination (ie, an anxious preoccupation with pain and the inability to inhibit pain-related thoughts and fears), magnification (ie, the tendency to amplify the significance of pain with respect to implications for one's global health), and helplessness (ie, despair surrounding perceived inability to control one's pain experience).[@b15-jpr-8-021] Accordingly, high levels of pain catastrophizing have been shown to predict high levels of acute and persistent pain after various surgeries.[@b16-jpr-8-021],[@b17-jpr-8-021] Further, a recent systematic review of psychological risk factors for pain in total knee and hip arthroplasty included catastrophizing as a potential risk factor, although the search strategy employed was somewhat limited leading to the omission of key studies.[@b18-jpr-8-021]

Although prospective studies have emphasized the role of pain catastrophizing as a risk factor for poor pain outcomes following surgical procedures including TKA,[@b19-jpr-8-021] the majority of research has employed the outcome of acute pain (ie, \<3 months following surgery).[@b20-jpr-8-021] Whereas acute pain tends to be proportionate to the degree of tissue damage and is generally functional, pain that persists for ≥3 months duration is considered chronic given that such pain exceeds typical physical healing time and often constitutes its own disorder that perpetuates functional disability.[@b21-jpr-8-021] However, the association between pain catastrophizing and chronic pain outcomes remains to be specifically and systematically analyzed in TKA populations. Thus, to clarify our understanding of a potentially modifiable psychological risk factor for a major surgical complication, we aimed to systematically review the literature that reported the prospective impact of pain catastrophizing on pain that persists ≥3 months after TKA.

Methods
=======

Search strategy
---------------

We conducted a literature search of MEDLINE (January 1, 1946--August 25, 2014), EMBASE (January 1, 1980--August 25, 2014), and PsycINFO (January 1, 1872--August 25, 2014) databases. Our search strategy employed mapped medical subject headings (MeSH) terms combined with keywords for unindexed terms related to the themes of pain catastrophizing, TKA, risk factors, and chronic pain (see [Table 1](#t1-jpr-8-021){ref-type="table"} for detailed search strategy). Additional articles were identified through a manual search of relevant bibliographies.

Study selection
---------------

After removal of duplicates, two authors (LB, SR) independently reviewed titles and abstracts to identify published studies that met our systematic review inclusion criteria of: 1) pain catastrophizing exposure; 2) TKA patient population; 3) chronic pain outcome (ie, assessed ≥3 months postoperatively); 4) prospective and longitudinal study design (eg, cohort, case--control studies with measurement of exposure prior to outcome); 5) original research paper; and 6) English language. We excluded non-primary literature (eg, reviews and commentaries), non-peer reviewed studies (eg, graduate theses), and conference proceedings. Any discrepancies in the selection of articles were resolved via consensus. After a manual search of relevant bibliographies to identify additional articles, abstracts that met our inclusion criteria were forwarded for full-text review. Two authors (LB and SR) independently assessed full-text articles for inclusion on the basis of the eligibility criteria, and any discrepancies were resolved via consensus.

Quality assessment
------------------

To assess the methodological quality of included studies, we adapted a checklist based on an established quality assessment instrument from the orthopedic literature.[@b22-jpr-8-021],[@b23-jpr-8-021] Two reviewers (LB and JK) independently scored the included studies according to 14 quality criteria ([Table 2](#t2-jpr-8-021){ref-type="table"}). Each criterion that was met was assigned a score of 1 and each that was not (or with insufficient information provided to assess) was assigned a score of 0. Any discrepancies were resolved via consensus. The maximum potential score for cohort designs (ie, study groups assigned based on exposure) was 14 and the maximum potential score for case--control designs (ie, study groups assigned based on outcome) was 13. The quality rating for each study was reported as the percentage of obtained scores out of the maximum potential score.[@b22-jpr-8-021]

Data abstraction and synthesis
------------------------------

We developed standardized data abstraction forms for uniform data capture across raters. Two authors (LB and SR) abstracted the data for each article and another (JK) verified the accuracy of the abstracted data. For each included study, we obtained the following information: citation, country, patient population, sample size, age, sex, body mass index (BMI), study design, follow-up time, exposure (pain catastrophizing) definition, outcome (pain) definition, analysis type, adjusted covariates/confounders, and main results. Due to the heterogeneity in reported pain outcomes, statistical analyses, and follow-up periods across identified studies, a quantitative meta-analysis could not be performed.

Results
=======

Literature search results
-------------------------

We identified 17,425 articles after the removal of duplicates ([Figure 1](#f1-jpr-8-021){ref-type="fig"}). Following title and abstract review, 23 full-text articles were assessed and excluded for the following reasons: no pain catastrophizing exposure (n=2); no chronic pain (≥3 months after surgery) outcome (n=2); no TKA population/no TKA-specific results (n=5); and incorrect study type (eg, reviews, commentaries; n=14). Overall, six studies met our eligibility criteria. Characteristics and quality ratings of included studies are summarized in [Table 2](#t2-jpr-8-021){ref-type="table"}.

Overview of studies
-------------------

We identified six studies[@b5-jpr-8-021],[@b24-jpr-8-021]--[@b28-jpr-8-021] (S1--S6 in [Tables 3](#t3-jpr-8-021){ref-type="table"} and [4](#t4-jpr-8-021){ref-type="table"}) that assessed the impact of pain catastrophizing on chronic post-surgical TKA pain. Details of studies are summarized in [Table 3](#t3-jpr-8-021){ref-type="table"} and extracted results are presented in [Table 4](#t4-jpr-8-021){ref-type="table"}. Sample sizes ranged from 55 to 215 participants and females constituted between 45% and 73% of study samples. Among studies that assessed BMI, patients tended to fall in the obese I/II range. Length of follow-up ranged from 3 months to 24 months. All studies measured the pain catastrophizing exposure preoperatively and employed reliable and valid assessment tools (five studies employed the pain catastrophizing scale[@b15-jpr-8-021] and one used the catastrophizing subscale of the Coping Strategies Questionnaire.[@b29-jpr-8-021] Study designs included cohort, case--control, and lagged analyses, and considerable variability was observed with respect to outcome definitions for chronic pain. Studies measured the main outcome of pain using a variety of instruments, including the Short-Form McGill Pain Questionnaire (SF-MPQ),[@b30-jpr-8-021] Brief Pain Inventory (BPI),[@b31-jpr-8-021] Western Ontario and McMaster University Osteoarthritis Index (WOMAC) pain score,[@b32-jpr-8-021] and a variety of pain rating scales (eg, 10 cm visual analog scale \[VAS\], 21-point numerical rating scale \[NRS\], 0--100 scale).[@b33-jpr-8-021] Pain intensity/severity was assessed with the patient resting, in response to range-of-motion exercises, thermal testing, pressure algometry, as a daily global score, and as nighttime pain. Moreover, pain was reported as an absolute value, a change from baseline, and/or as the number/percent of patients reporting pain scores above or below a certain threshold. The methodologic quality of studies was generally acceptable ([Table 2](#t2-jpr-8-021){ref-type="table"}), although one study did not control for confounding. Key evidence is synthesized below with consideration given to type of study type, exposure, and outcome measurements used, and follow-up time.

Cohort studies
--------------

We identified two prospective cohort studies (S3 and S6) from France and Canada that reported the impact of preoperative pain catastrophizing on chronic pain following TKA surgery. In both cases, multivariable linear regression was used with adjustment for relevant confounders including baseline age, sex, preoperative pain, and medical/psychological covariates (S3 for comorbidities, anxiety, and depression; S6 for fear of movement and depression). Pain medication/analgesic use was not reported or controlled for in either case. Both studies measured the catastrophizing exposure using the Pain Catastrophizing Scale (PCS) and pain intensity was measured as a continuous outcome variable (S3, BPI; S6, WOMAC pain scale). In S3, increased levels of magnification (PCS-M subscore) independently predicted elevated pain intensity among 89 TKA patients (100% follow-up rate) at 3 months (*β*=0.14, *SE* =0.05; *t*=2.06; *P*=0.04; [Table 4](#t4-jpr-8-021){ref-type="table"}). Similarly, S6 found that heightened catastrophizing (overall score) independently predicted increased pain ratings among 120 TKA patients 1 year postoperatively, (*β*=0.27, *P*\<0.05; [Table 4](#t4-jpr-8-021){ref-type="table"}). Further, they showed that behavioral outcome expectancies measured before surgery partially mediated the relationship between pain catastrophizing and 6-month follow-up WOMAC pain scores, which provides some evidence for potential intervention targets to help reduce chronic pain after TKA. Because the authors did not report on loss to follow-up, the impact of this potential bias cannot be determined.

Though not a traditional cohort study, we identified one additional study that used prospectively collected pain catastrophizing scores to predict subsequent pain intensity ratings as a continuous outcome variable (S1). This small (n=43) US study (2009) employed generalized estimating equations (GEE) to conduct a lagged analysis with repeated measures of pain catastrophizing and pain severity at baseline (preoperatively) and 1 month, 3 months, 6 months, and 12 months follow-up. The authors leveraged the power of GEE to compensate for their small sample size and incomplete data capture over follow-up by allowing pain outcomes to be predicted by a pain catastrophizing score at any previous time point. The authors measured catastrophizing using the Coping Strategies Questionnaire--Catastrophizing Subscale (all other studies employed the PCS) and pain ratings were measured using a 0--100 scale. Multivariate adjustment was made for time point, pain, and depression; due to the repeated-measures design, demographic factors were also inherently controlled. Analgesic or other pain medication use was not reported. Before adding depression to their multivariable model, global daily (past 24 h) and nighttime pain severity at each time point were positively related to pain catastrophizing levels at the previous time point. However, when depression was added to the daily global pain model, the effect of pain catastrophizing lost significance and only pain at the previous point and depression contributed significantly to the explanation of global daily pain. In contrast, after depression was added to the nighttime pain model, pain catastrophizing remained significant (global pain estimate =2.1; *SE* =2.2; *t*=0.9; *P*=0.35; nighttime pain estimate =5.1; *SE* =2.5; *t*=2.0; *P*=0.04; [Table 4](#t4-jpr-8-021){ref-type="table"}), although its contribution was reduced. These results suggest some degree of collinearity between depression and pain catastrophizing. Despite overall decreases in pain levels over time, pain catastrophizing levels did not vary significantly from baseline to the end of follow-up ([Table 4](#t4-jpr-8-021){ref-type="table"}). Together, these findings suggest that catastrophizing may constitute a stable driver of future pain severity in the year following TKA. It should be noted that the initial follow-up period (baseline to 1 month) violated our inclusion criterion of ≥3 months follow-up for chronic pain and could thus lead to some contamination of results; however, we retained this study for evidence synthesis given that the majority of the model variance was derived from the other assessment time points, by which time the pain was longstanding enough to fit with our definition of chronic. Nonetheless, the higher proportion of individuals with pain at 1 month follow-up may have led to a slight overestimation of the impact of pain catastrophizing on subsequent pain variability.

Case--control studies
---------------------

Four studies (S2, S3, S4, and S5) assessed the impact of pain catastrophizing according to several dichotomized outcome definitions of chronic pain, which differed across all included studies. Among these, two studies (one from the US \[S4, n=215\] and one from France \[S3; n=89\]) used multivariate logistic regression to assess whether higher pain catastrophizing (PCS) scores increased the odds of clinically-relevant pain levels persisting after TKA surgery. The US case--control study was nested within an existing randomized clinical trial (RCT) of transcutaneous electrical nerve stimulation (TENS). This study (S4) defined "cases" as those with "moderate-to-severe pain intensity" (ie, a score ≥8 on a 21-point NRS for pain), whereas the latter (S3) defined "cases" as those with a "clinically-meaningful" pain intensity (ie, a score of ≥3/10 on the BPI). Both studies adjusted for relevant baseline covariates including age, sex, pain, depression, and anxiety, and S4 additionally adjusted for medical comorbidities, fear of movement/re-injury, and RCT treatment arm. In both cases, pain catastrophizing was not found to be an independent predictor of clinically relevant pain levels at follow-up (*P*\>0.05; [Table 4](#t4-jpr-8-021){ref-type="table"}). Neither of these studies reported odds ratios (ORs) with confidence intervals (CIs) for the TKA patients, masking potential trends and precluding future meta-analysis. Further, pre-operative anxiety emerged as an important predictor in both final models; however, the authors did not publish univariate or stepwise results from their logistic models. Thus, it remains unclear whether pain catastrophizing would have conferred a significant risk before depression and anxiety were added as covariates, which could again indicate collinearity of these constructs.

Another small scale study (S2; n=55) assessed the impact of pain catastrophizing on a dichotomized definition of pain defining the presence of non-zero pain at 24 months follow-up as the primary outcome. The authors used two instruments to assess their outcome of non-zero pain: 1) the Short-Form MPQ--Pain Rating Index (PRI), which asks participants to rate adjectives that describe qualitative aspects of pain on a 4-point scale, and 2) the MPQ--VAS. Because the data were skewed, the authors employed Mann--Whitney *U* tests and receiver operating characteristic (ROC) curve analysis to assess the impact of catastrophizing on non-zero pain presence. The model using the adjective-based measure of non-zero pain (ie, MPQ--PRI), showed that both the total PCS score (PCS-T) and the rumination subscore (PCS-R) were significant predictors of the outcome (PCS-T, *P*=0.028, area under the curve =0.71; PCS-R, *P*=0.043, area under the curve =0.70). When the MPQ--VAS score was employed, however, the effect of catastrophizing lost significance (*P*'s from 0.56 to 0.71; [Table 4](#t4-jpr-8-021){ref-type="table"}). It is likely that the MPQ--PRI constitutes a more sensitive measure of variation among individuals with low-level pain because it prompts participants to consider different aspects of their pain experience, of importance in studies with extended follow-up intervals where floor effects can make relations difficult to detect. Nonetheless, caution should be exercised when interpreting these results given the small sample size, non-parametric analyses, failure to adjust for any covariates, and failure to adjust for multiple analyses, all of which increase the likelihood of false-positive findings.

Finally, we identified a mid-sized (n=140) US case--control study (S5) that used TKA treatment failure (insufficient pain reduction) at 6 months follow-up as the case definition. The authors also used the PCS to measure preoperative pain catastrophizing, but chose to dichotomize this predictor variable according to high vs low catastrophizers. High catastrophizers were arbitrarily defined as those individuals in the highest tertile of obtained scores, corresponding to PCS scores ≥16, and all others were designated as low catastrophizers. It is noteworthy that the PCS manual provides cut-off scores for problematic pain catastrophizing; the selected threshold of ≥16 constitutes the cut-off score for the 41st percentile.[@b34-jpr-8-021] Treatment failure was operationalized both in terms of 1) \<50% improvement in WOMAC pain scores from baseline; and 2) \<4 point improvement in WOMAC pain scores (based on sensitivity analysis of patient-defined clinical relevance). After adjustment for covariates including baseline age, sex, pain, comorbidities, and fear of movement, the authors found that high catastrophizers had substantially increased odds of treatment failure according to \<50% WOMAC pain improvement (OR =2.67) and \<4 point WOMAC pain improvement (OR =6.04) ([Table 4](#t4-jpr-8-021){ref-type="table"}). The authors did not adjust for depression, anxiety, or analgesic use, which could potentially covary with pain catastrophizing or confound the associations under investigation. Furthermore, the authors noted that of 157 individuals assessed at baseline, 129 underwent TKA, whereas 28 underwent unicompartmental (or partial) knee arthroplasty (UKA), which is a simpler operation indicated among individuals with lower disease severity. Only 140 patients completed follow-up assessments and were ultimately included in the case--control analysis, although the authors did not report on the composition of TKA vs UKA participants included in the final sample. It should be noted that inclusion of UKA individuals in the study population is a technical violation of our inclusion criteria; however, we retained the study in the systematic review because the majority of the variability would derive from the TKA patients. Although it is not possible to assess the specific degree of contamination conferred by UKA patients to the results, these individuals would likely have less intense overall pain (and less variability in pain) at follow-up, and thus, their inclusion would likely bias estimates toward the null should they have any impact. The authors did not conduct a sensitivity analysis to assess the impact of using alternate cut-offs for high catastrophizers, which would be of high clinical relevance for screening purposes.

Impact of follow-up length
--------------------------

Follow-up of included studies ranged from 3 months to 24 months. Overall, there was no clear indication that length of follow-up modified the relationship between preoperative pain catastrophizing and chronic pain outcomes during the time interval studied. The study with the shortest follow-up time of 3 months (S3, [Tables 3](#t3-jpr-8-021){ref-type="table"} and [4](#t4-jpr-8-021){ref-type="table"}) found that pain catastrophizing predicted pain intensity but not clinically-meaningful pain when measured as a dichotomous measure, likely reflecting power limitations. Between the two studies with 6-month follow-up that assessed pain treatment failure and presence of moderate-to-severe pain (S5 and S4, respectively), the former found a 2.7- to six-fold increased risk for high-pain catastrophizers, whereas the latter failed to observe a significant relationship. Between the two studies with \>1 year follow-up, the larger, more methodologically-rigorous study (S6) found an effect of catastrophizing on pain intensity, whereas the smaller unadjusted study (S2) found mixed results for an effect on non-zero pain, a divergence that likely reflects sensitivity differences in pain measures used. Thus, while length of follow-up may not interact with the strength of relation between pain catastrophizing and chronic pain outcomes, a floor effect may occur due to fewer chronic pain cases and/or general reductions in pain intensity with time.

Discussion
==========

The objective of this systematic review was to provide a synthesis of the evidence to date on pain catastrophizing as a prospective risk factor for chronic pain (ie, persisting ≥3 months) after TKA. Overall, five out of the six identified studies were able to detect some effect of pain catastrophizing on chronic pain outcomes using at least one outcome measure. Although large-scale data were not available, two mid-sized multivariate cohort studies (S3 and S6) found a positive effect of pain catastrophizing on chronic pain intensity following TKA surgery independent of baseline demographics, pain levels, and psychological factors. Whereas, two mid-sized multivariate case--control analyses (S3 and S4) failed to replicate such an effect when clinically-meaningful pain thresholds were employed as case definitions and additional adjustment was made for anxiety and depression, another multivariable case--control study found that high pain catastrophizers had dramatically increased odds of TKA-treatment failure with respect to chronic pain outcomes (S5). A lagged analysis (S1) found that pain catastrophizing remained a stable predictor of future pain severity over 1 year follow-up, and a small unadjusted (S2) study found a measurable effect of catastrophizing on non-zero pain 2 years postoperatively. These data provide a moderate level of evidence that high pain catastrophizing is a risk factor for chronic pain following TKA.

A major shortcoming in all identified studies was failure to report and adjust for analgesic use in multivariate models. It is possible that high pain catastrophizers had lower adherence to pain medications, perhaps due to heightened concerns regarding potential side-effects, which in turn may have led to poorer pain control at follow-up, thus confounding the investigated relations.

Another important consideration that remains to be resolved is whether other psychological constructs (such as anxiety and depression), which are known to be related to pain catastrophizing, were measured and included as covariates in the model predicting chronic pain. For example, the global pain rating parameter estimate for pain catastrophizing in the lagged analysis (S1) lost significance after further inclusion of depression in the model, although nighttime pain remained significant after inclusion of depression. Further, the two non-significant case--control analyses that used clinically meaningful outcomes (S3 and S4) adjusted for anxiety and depression, although their potential impact on catastrophizing estimates was not reported. These studies suggest that depression and anxiety may be more relevant exposures, and to the extent that these are causally related to development of chronic pain, there are well-established treatments for both. In contrast, pain catastrophizing remained an independent predictor after controlling for anxiety (S3) and/or depression (S3, S4) in the two prospective multivariable cohort studies, which together constitute the highest level of evidence available to date. Taken together, we currently lack sufficient evidence to conclude which risk factor(s) among the many related psychological constructs (eg, pain catastrophizing, anxiety, and depression) contribute uniquely to chronic pain after TKA.

In general, pain catastrophizing levels remained stable over follow-up, whereas pain levels gradually diminished, on average ([Table 4](#t4-jpr-8-021){ref-type="table"}). However, length of follow-up did not appear to modify the effect of catastrophizing on chronic pain outcomes measured, with no clear pattern of significance/non-significance observed as follow-up intervals increased. Rather, detection of a pain catastrophizing effect appeared to depend more on adequate power. Thus, the primary consideration in studies with lengthy follow-up periods (ie, \>1 year) should be ensuring adequate numbers of cases or sufficient sensitivity in outcome measures to detect minor variability in low-grade pain. Nevertheless, without statistical analysis of large-scale data that models baseline catastrophizing on repeated pain measures over time, an interaction effect of follow-up time on the investigated relationship cannot be completely dismissed.

We observed substantial heterogeneity in studies with respect to study designs, analyses employed, multivariate adjustments, measures used, and outcome reporting. Of particular importance, each study we identified employed a different outcome measure for pain. The failure to adopt standardized outcome measures of pain intensity as well as a relevant cut-off for clinically-meaningful pain precludes direct comparison of results and limits opportunities for meta-analysis. Authors did not typically report stepwise results of multivariate models or univariate parameter estimates to aid the reader in understanding the impact of collinearity. Furthermore, the identified studies did not report specific parameter estimates or confidence intervals for non-significant findings, limiting their interpretation and further precluding meta-analysis of small sample data. For instance, although three studies used logistic regression to assess the impact of pain catastrophizing on pain outcomes (S3, S4, S5), only the study with significant results (S5) presented ORs and CIs. Assessment of exposure was more consistent, with five of six studies employing the PCS. However, the one study that dichotomized patients as high vs low pain catastrophizers (a potentially valuable clinical distinction) failed to provide data on the validity of their threshold.

To improve future data capture, the field would benefit from the adoption of the Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials consensus guidelines for standardized reporting of clinically relevant pain outcomes in RCTs, which have direct relevance to both cohort and case--control studies as well.[@b19-jpr-8-021],[@b35-jpr-8-021]--[@b37-jpr-8-021] Multivariable adjustment should include analgesic use (type, dose), depression, and anxiety, in addition to traditional clinical risk factors. Further, investigation of the optimal PCS cut-off for 'high pain catastrophizers' in predicting adverse post-surgical pain outcomes (ROC analysis) would both set the stage for its inclusion in disease complexity measures in future investigations and would be of high clinical relevance as a practical screening tool. Finally, studies should report parameter and confidence estimates for non-significant findings so that future investigators may pool their data for powerful meta-analyses.

Strengths and limitations of our systematic review deserve comment. Strengths of our review include a comprehensive and replicable research strategy with two independent raters and quality assessment of all articles by three independent raters, as well as a systematic approach to evidence synthesis on the predictive value of catastrophizing on chronic post-TKA pain. A limitation of our review is that the identification and selection of relevant articles may have been influenced by publication bias (ie, underreporting of non-significant findings). Further, due to the heterogeneity in data capture and reporting across the included studies, a quantitative meta-analysis was not possible.

Although further well-controlled and large-scale data would be valuable, the current evidence provides moderate support that pain catastrophizing is an important risk factor for chronic pain following TKA surgery. Given that pain catastrophizing constitutes a modifiable response to threat among other populations of chronic pain patients[@b38-jpr-8-021]--[@b40-jpr-8-021] and to the extent that it is a causal risk factor, interventions aimed at reducing pain catastrophizing symptoms[@b41-jpr-8-021] may translate to improved pain outcomes of TKA. As rates of TKA continue to increase with the aging population and rising obesity epidemic,[@b1-jpr-8-021],[@b3-jpr-8-021] further clarification of the prognostic value of various pain catastrophizing levels holds promise to close the gap in TKA recovery outcomes.
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###### 

Mapped medical subject headings (MeSH) terms and keywords employed in electronic search strategy

  Concept                   MeSH terms                                                                                                                                                                                                                                        Keywords
  ------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------
  Catastrophizing           Catastrophization; behavioral symptoms; behavioral medicine; stress, psychological; health behavior; psychology, social; mental disorders; anxiety; anxiety disorders; neurotic disorders; personality; attitude to health                        Catastrophiz\*; emotional; attitud\*; coping; pain catastrophizing scale; PCS
  Total knee arthroplasty   General surgery; postoperative complications; total knee replacement                                                                                                                                                                              Surgery; post-surg\*; postsurg\*; post-operati\*; postoperati\*; TKA; TKR
  Risk factors              Risk; proportional hazards models; regression analysis; logistic models; risk factors; models, statistical; survival analysis; epidemiologic research design; epidemiology; epidemiologic methods; epidemiologic studies; models, psychological   Risk factor\*; predict\*
  Chronic pain              Pain; postoperative; chronic pain; pain, intractable                                                                                                                                                                                              Pain

**Abbreviations:** PCS, Pain Catastrophizing Scale; TKA, total knee arthroplasty; TKR, total knee replacement.

###### 

Quality assessment of studies included in systematic review

                                                                                                  Edwards et al[@b5-jpr-8-021], 2009 \[S1\]   Forsythe et al[@b24-jpr-8-021], 2008 \[S2\]   Masselin-Dubois et al[@b25-jpr-8-021], 2013 \[S3\]   Noiseux et al[@b26-jpr-8-021], 2014 \[S4\]   Riddle et al[@b27-jpr-8-021], 2010 \[S5\]   Sullivan et al[@b28-jpr-8-021], 2011 \[S6\]
  ----------------------------------------------------------------------------------------------- ------------------------------------------- --------------------------------------------- ---------------------------------------------------- -------------------------------------------- ------------------------------------------- ---------------------------------------------
  Q1--Clear description of selection of study subjects                                            1                                           1                                             1                                                    1                                            0                                           1
  Q2--Formal power/sample size calculation                                                        0                                           0                                             0                                                    0                                            1                                           0
  Q3--Number of subjects assessed for eligibility vs enrolled adequately described                0                                           1                                             1                                                    1                                            1                                           0
  Q4--Sufficient description of characteristics of subjects                                       1                                           1                                             1                                                    1                                            0                                           1
  Q5--Participation rate ≥80% for study groups                                                    0                                           0                                             0                                                    0                                            0                                           0
  Q6--Attrition documented                                                                        0                                           1                                             1                                                    1                                            1                                           0
  Q7--Pain catastrophizing exposure measured with valid and reliable tool                         1                                           1                                             1                                                    1                                            1                                           1
  Q8--Pain outcome(s) measured with valid and reliable tool                                       0                                           1                                             1                                                    1                                            1                                           1
  Q9--Distribution of comorbidities/covariates provided for study groups                          1                                           N/A                                           1                                                    N/A                                          N/A                                         1
  Q10--Comorbidity/covariates measured identically in study groups                                1                                           1                                             1                                                    1                                            1                                           1
  Q11--Results adjusted for potential confounders (minimally: age, sex, and pre-op pain rating)   1                                           0                                             1                                                    1                                            1                                           1
  Q12--Results adjusted for psychosocial factors (minimally: anxiety and depression)              0.5                                         0                                             1                                                    1                                            1                                           0.5
  Q13--Appropriate analysis techniques used                                                       1                                           0                                             1                                                    1                                            1                                           1
  Q14--Sufficient info given on association (effect) sizes                                        1                                           1                                             1                                                    1                                            1                                           1
  Obtained score                                                                                  8.5                                         8.5                                           12                                                   11                                           10                                          9.5
  Potential score                                                                                 14                                          13                                            14                                                   13                                           13                                          14
  Quality rating, % (obtained/potential score × 100)                                              **61**                                      **65**                                        **86**                                               **85**                                       **77**                                      **68**

**Note:** N/A, not applicable (presentation of covariate distribution across study \[S1--S6\] groups is not appropriate in case--control studies, since baseline covariates are confounded by outcome).

###### 

Characteristics of studies included in systematic review

  Study ID   Reference                               Country   Patient Population   N     Age (years)                                   Female, N (%)                                      BMI (kg/m^2^)                                   Study design                                             Follow-up (months)   Outcomes reported
  ---------- --------------------------------------- --------- -------------------- ----- --------------------------------------------- -------------------------------------------------- ----------------------------------------------- -------------------------------------------------------- -------------------- ---------------------------------------------------
  S1         Edwards et al[@b5-jpr-8-021]            USA       TKA                  43    72±7                                          25 (58)                                            NR                                              Cohort with lagged analysis                              1, 3, 6, 12          Overall and nighttime pain severity
  S2         Forsythe et al[@b24-jpr-8-021]          Canada    TKA                  55    69 (range, 49--85)                            35 (64)                                            NR                                              Case--control                                            24                   Non-zero pain presence
  S3         Masselin-Dubois et al[@b25-jpr-8-021]   France    TKA                  89    69±9                                          65 (73)                                            NR                                              Cohort and case--control                                 3                    Clinically-meaningful pain presence and intensity
  S4         Noiseux et al[@b26-jpr-8-021]           USA       TKA                  215   62±10                                         125 (58)                                           38±11                                           Case--control[a](#tfn3-jpr-8-021){ref-type="table-fn"}   6                    Moderate-to-severe pain presence
  S5         Riddle et al[@b27-jpr-8-021]            USA       TKA/UKA              140   64[b](#tfn4-jpr-8-021){ref-type="table-fn"}   71 (45)[b](#tfn4-jpr-8-021){ref-type="table-fn"}   31±7[b](#tfn4-jpr-8-021){ref-type="table-fn"}   Case--control[a](#tfn3-jpr-8-021){ref-type="table-fn"}   6                    Failure to meaningfully reduce pain
  S6         Sullivan et al[@b28-jpr-8-021]          Canada    TKA                  120   67 (range 50--85)                             73 (61)                                            31 (range 20--45)                               Cohort                                                   12                   Pain intensity

**Notes:**

The authors described the study as a cohort study, although cases and controls were defined by outcome

based on 157 patients eligible for follow-up, although only 140 completed follow-up.

**Abbreviations:** BMI, body mass index; NR, not reported; TKA, total knee arthroplasty; UKA, unicompartmental knee arthroplasty.

###### 

Exposures, outcomes, analyses, confounders, and results of studies included in systematic review

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study ID   Author                                  Catastrophizing (exposure) definition                                                                            Outcome (pain) definition                                       Catastrophizing over follow-up                         Pain over follow-up                              Analysis                                                                               Adjusted covariates                                                                                                                                                                                                   Main results
  ---------- --------------------------------------- ---------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------- ------------------------------------------------------ ------------------------------------------------ -------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------
  S1         Edwards et al[@b5-jpr-8-021]            CSQ-Catastrophizing \[C\] Subscale, assessed at previous time point (Continuous)                                 Pain severity:\                                                 CSQ-C (0--36)\                                         *Global daily pain (0--100)*\                    Lagged analysis (GEE used to model correlation of repeated measures within subjects)   Time point, overall pain,^a^ nighttime pain,^a^ depression^a^                                                                                                                                                         1\) Estimate =2.1; *SE* =2.2; *t*=0.9; *P*=0.35;\
                                                                                                                                                                      1) global daily pain, past 24 hours (0--100 scale) and;\        Pre-op: 3.8±3.9\                                       Pre-op: 58.8±23.0\                                                                                                                                                                                                                                                                                                                                            2) Estimate =5.1; *SE* =2.5; *t*=2.0; *P*=0.04
                                                                                                                                                                      2)Nighttime pain (0--100 scale) (Continuous)                    1 month: 4.5±6.4\                                      1 month: 29.8±26.6\                                                                                                                                                                                                                                                                                                                                           
                                                                                                                                                                                                                                      3 months: 4.4±5.1\                                     3 months: 21.0±25.9\                                                                                                                                                                                                                                                                                                                                          
                                                                                                                                                                                                                                      6 months: 4.0±5.4\                                     6 months: 13.3±19.9\                                                                                                                                                                                                                                                                                                                                          
                                                                                                                                                                                                                                      12 months: 3.8±5.4                                     12 months: 11.0±19.7;\                                                                                                                                                                                                                                                                                                                                        
                                                                                                                                                                                                                                                                                             *Nighttime pain (0--100)*\                                                                                                                                                                                                                                                                                                                                    
                                                                                                                                                                                                                                                                                             Pre-op: 40.7±32.1\                                                                                                                                                                                                                                                                                                                                            
                                                                                                                                                                                                                                                                                             1 month: 31.5±29.8\                                                                                                                                                                                                                                                                                                                                           
                                                                                                                                                                                                                                                                                             3 months: 18.1±23.7\                                                                                                                                                                                                                                                                                                                                          
                                                                                                                                                                                                                                                                                             6 months: 11.6±19.6\                                                                                                                                                                                                                                                                                                                                          
                                                                                                                                                                                                                                                                                             12 months: 8.9±16.8                                                                                                                                                                                                                                                                                                                                           

  S2         Forsythe et al[@b24-jpr-8-021]          PCS Total \[T\] and subscales for Helplessness \[H\], Magnification \[M\], and Rumination \[R\] (Continuous)     Non-zero pain presence on\                                      PCS-T (0--52)\                                         *SF-MPQ-PRI (0--45):*\                           Mann--Whitney *U* with ROC curve analysis (with vs without pain at follow up)          N/A (insufficient N)                                                                                                                                                                                                  1\) PCS-R, *P*=0.043, AUC =0.70, 95% CI, 0.54--0.86; PCS-T, *P*=0.028, AUC =0.71, 95% CI, 0.56--0.87;\
                                                                                                                                                                      1) SF-MPQ-PRI; and\                                             Pre-op: 9.8±8.7\                                       Pre-op: 17.8±8.1\                                                                                                                                                                                                                                                                                                                                             2) Catastrophizing *NS* (*P*'s from 0.56 to 0.71)
                                                                                                                                                                      2) SF-MPQ-VAS (Dichotomous)                                     3 months 10.0±8.2\                                     3 months: 10.1±8.3\                                                                                                                                                                                                                                                                                                                                           
                                                                                                                                                                                                                                      12 months: 8.8±9.6\                                    12 months: 8.4±9.3\                                                                                                                                                                                                                                                                                                                                           
                                                                                                                                                                                                                                      24 months: 9.8±9.3                                     24 months: 7.6±8.7;\                                                                                                                                                                                                                                                                                                                                          
                                                                                                                                                                                                                                                                                             *SF-MPQ-VAS (0--10):*\                                                                                                                                                                                                                                                                                                                                        
                                                                                                                                                                                                                                                                                             Pre-op: 6.8±1.9\                                                                                                                                                                                                                                                                                                                                              
                                                                                                                                                                                                                                                                                             3 months: 3.3±2.7\                                                                                                                                                                                                                                                                                                                                            
                                                                                                                                                                                                                                                                                             12 months: 2.7±3.0\                                                                                                                                                                                                                                                                                                                                           
                                                                                                                                                                                                                                                                                             24 months: 2.2±2.3                                                                                                                                                                                                                                                                                                                                            

  S3         Masselin-Dubois et al[@b25-jpr-8-021]   PCS with subscales for Helplessness \[H\], Magnification \[M\], Rumination \[R\], and Total \[T\] (Continuous)   1\) Clinically-meaningful pain: BPI ≥3/10 (Dichotomous); and\   PCS-T (0--52)\                                         *% BPI* ≥*3/10:*\                                Multivariable logistic and linear regression                                           Baseline: age, sex, radiotherapy, chemotherapy, BPI, pain duration (yrs), anxiety, depression                                                                                                                         1\) Catastrophizing NS, *P*\>0.05;\
                                                                                                                                                                      2) Pain intensity: BPI score (Continuous)                       Pre-op (all patients):\                                Pre-op: 84\                                                                                                                                                                                                                                                                                                                                                   2) PCS-M *β*=0.14, *SE* =0.05; *t*=2.06; *P*=0.04
                                                                                                                                                                                                                                      19.4±11.2 3 months (patients with BPI ≥3/10) 3.3±2.7   3 months: 50.6                                                                                                                                                                                                                                                                                                                                                

  S4         Noiseux et al[@b26-jpr-8-021]           PCS score (Continuous)                                                                                           Moderate to severe pain intensity: NRS ≥8/21 (Dichotomous)      NR                                                     *Pain with ROM (%):*\                            Multivariable logistic regression                                                      Baseline: age, sex, comorbidity score, marital status, RA status, ethnicity, pain score, surgeon, hospital, TSK, depression, anxiety, treatment received (TENS vs placebo)[b](#tfn7-jpr-8-021){ref-type="table-fn"}   Catastrophizing NS, *P*\>0.05
                                                                                                                                                                                                                                                                                             Pre-op:\                                                                                                                                                                                                                                                                                                                                                      
                                                                                                                                                                                                                                                                                             Low: 48%\                                                                                                                                                                                                                                                                                                                                                     
                                                                                                                                                                                                                                                                                             Moderate: 35%\                                                                                                                                                                                                                                                                                                                                                
                                                                                                                                                                                                                                                                                             Severe: 17%\                                                                                                                                                                                                                                                                                                                                                  
                                                                                                                                                                                                                                                                                             *6 months:*\                                                                                                                                                                                                                                                                                                                                                  
                                                                                                                                                                                                                                                                                             Low: 84%\                                                                                                                                                                                                                                                                                                                                                     
                                                                                                                                                                                                                                                                                             Moderate:14%\                                                                                                                                                                                                                                                                                                                                                 
                                                                                                                                                                                                                                                                                             Severe: 2%                                                                                                                                                                                                                                                                                                                                                    

  S5         Riddle et al[@b27-jpr-8-021]            High catastrophizers: top tertile of obtained scores (PCS ≥16) (Dichotomous)                                     Treatment failure:\                                             NR                                                     *WOMAC pain % improvement:* 6 months: 53.6±39%   Multivariable logistic regression                                                      Baseline: age, sex, comorbidity score, RA status, ethnicity, pain score, surgeon, hospital, TSK                                                                                                                       1\) OR =2.67 (1.2--6.1);\
                                                                                                                                                                      1) \<50% improvement; and\                                                                                                                                                                                                                                                                                                                                                                                                                                                           2) OR =6.04 (1.75--20.81)
                                                                                                                                                                      2) \<4 points improvement in WOMAC pain score (Dichotomous)                                                                                                                                                                                                                                                                                                                                                                                                                          

  S6         Sullivan et al[@b28-jpr-8-021]          PCS score (Continuous)                                                                                           Pain severity:\                                                 PCS-T (0--52)\                                         *WOMAC pain score (0--20):*\                     Multivariable linear regression                                                        Baseline: age, sex, BMI, comorbidities, pain, physical function, surgery duration, surgeon, TSK, depression                                                                                                           *β*=0.27, *P*\<0.05
                                                                                                                                                                      WOMAC pain scale (Continuous)                                   Pre-op: 12.9±11.2                                      Pre-op: 10.6±3.5\                                                                                                                                                                                                                                                                                                                                             
                                                                                                                                                                                                                                                                                             6 months: 3.5±3.7                                                                                                                                                                                                                                                                                                                                             
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Note:**

Measured at previous time point

study was nested within an existing RCT.

**Abbreviations:** AUC, area under the curve; BMI, body mass index (kg/mg[@b2-jpr-8-021]); BPI, Brief Pain Inventory; CI, confidence interval; CSQ, Coping Strategies Questionnaire; GEE, generalized estimating equations; NR, not reported; NRS, Numerical Rating Scale; NS, not significant; OR, odds ratio; PCS, Pain Catastrophizing Scale; Pre-op, preoperative; PRI, Pain Rating Index; RA, rheumatoid arthritis; ROM, range of motion; SF-MPQ, Short-Form McGill Pain Questionnaire; TENS, transcutaneous electrical nerve stimulation; TSK, Tampa Scale of Kinesiophobia; WOMAC, Western Ontario and McMaster University Osteoarthritis Index; VAS, visual analog scale; vs, versus.
